Federated Hermes Inc. Increases Stock Position in AnaptysBio, Inc. $ANAB

Federated Hermes Inc. increased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 2,236.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 193,327 shares of the biotechnology company’s stock after purchasing an additional 185,053 shares during the quarter. Federated Hermes Inc. owned 0.69% of AnaptysBio worth $5,920,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in ANAB. Assenagon Asset Management S.A. lifted its holdings in shares of AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the last quarter. 683 Capital Management LLC raised its holdings in AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after acquiring an additional 304,373 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after acquiring an additional 233,325 shares during the period. Soleus Capital Management L.P. boosted its holdings in AnaptysBio by 214.6% in the second quarter. Soleus Capital Management L.P. now owns 321,040 shares of the biotechnology company’s stock valued at $7,127,000 after acquiring an additional 218,988 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in AnaptysBio in the second quarter valued at about $3,348,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Stifel Nicolaus cut their price objective on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Wells Fargo & Company raised their price objective on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. UBS Group started coverage on AnaptysBio in a research note on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Finally, Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and an average price target of $62.70.

AnaptysBio Stock Performance

ANAB opened at $50.54 on Tuesday. The stock’s 50 day moving average price is $46.27 and its 200-day moving average price is $34.16. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $52.47. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -17.92 and a beta of 0.35.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. As a group, analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has initiated a share repurchase program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, Director Magda Marquet sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total transaction of $530,530.00. Following the sale, the director owned 9,930 shares of the company’s stock, valued at $478,923.90. The trade was a 52.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul F. Lizzul sold 3,650 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $163,191.50. Following the transaction, the insider directly owned 42,088 shares in the company, valued at $1,881,754.48. The trade was a 7.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 146,280 shares of company stock valued at $6,714,939 over the last three months. Company insiders own 33.50% of the company’s stock.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.